Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.
Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Zucman D, Di Martino V, Bagnis CI, Ziol M, Sutton A, Letouze E, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir group.
Cacoub P, et al. Among authors: cagnot c.
Am Heart J. 2018 Apr;198:4-17. doi: 10.1016/j.ahj.2017.10.024. Epub 2017 Nov 7.
Am Heart J. 2018.
PMID: 29653647